183 related articles for article (PubMed ID: 35774514)
1. A Novel Defined Super-Enhancer Associated Gene Signature to Predict Prognosis in Patients With Diffuse Large B-Cell Lymphoma.
Xu H; Li Y; Jiang Y; Wang J; Sun H; Wu W; Lv Y; Liu S; Zhai Y; Tian L; Li L; Zhao Z
Front Genet; 2022; 13():827840. PubMed ID: 35774514
[No Abstract] [Full Text] [Related]
2. Identification and Validation of a Prognostic Prediction Model in Diffuse Large B-Cell Lymphoma.
Yan J; Yuan W; Zhang J; Li L; Zhang L; Zhang X; Zhang M
Front Endocrinol (Lausanne); 2022; 13():846357. PubMed ID: 35498426
[TBL] [Abstract][Full Text] [Related]
3. Ferroptosis-Related Gene Signature: A New Method for Personalized Risk Assessment in Patients with Diffuse Large B-Cell Lymphoma.
Chen H; He Y; Pan T; Zeng R; Li Y; Chen S; Li Y; Xiao L; Zhou H
Pharmgenomics Pers Med; 2021; 14():609-619. PubMed ID: 34079336
[TBL] [Abstract][Full Text] [Related]
4. A novel NET-related gene signature for predicting DLBCL prognosis.
Shi H; Pan Y; Xiang G; Wang M; Huang Y; He L; Wang J; Fang Q; Li L; Liu Z
J Transl Med; 2023 Sep; 21(1):630. PubMed ID: 37716978
[TBL] [Abstract][Full Text] [Related]
5. Construction of a Five-Super-Enhancer-Associated-Genes Prognostic Model for Osteosarcoma Patients.
Ouyang Z; Li G; Zhu H; Wang J; Qi T; Qu Q; Tu C; Qu J; Lu Q
Front Cell Dev Biol; 2020; 8():598660. PubMed ID: 33195283
[TBL] [Abstract][Full Text] [Related]
6. Identification and Development of a 4-Gene Ferroptosis Signature Predicting Overall Survival for Diffuse Large B-Cell Lymphoma.
Wu H; Zhang J; Fu L; Wu R; Gu Z; Yin C; He K
Technol Cancer Res Treat; 2023; 22():15330338221147772. PubMed ID: 36762399
[No Abstract] [Full Text] [Related]
7. Prognostic Significance of Ribosome-related Genes Signature in Diffuse Large B Cell Lymphoma.
Wu W; Wang J; Jiang Y; Hu X; Tian Y; Chen L; Sun H; Li Y; Liu S; Lv Y; Guo J; Xu H; Xing D; Zhai Y; Tian L; Li C; He X; Luo K; Pan Y; Zhao Z
J Cancer; 2023; 14(3):403-416. PubMed ID: 36860924
[No Abstract] [Full Text] [Related]
8. Super-Enhancer Associated Five-Gene Risk Score Model Predicts Overall Survival in Multiple Myeloma Patients.
Qi T; Qu J; Tu C; Lu Q; Li G; Wang J; Qu Q
Front Cell Dev Biol; 2020; 8():596777. PubMed ID: 33344452
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Prognostic Gene Signature for Diffuse Large B-Cell Lymphoma Based on Tumor Microenvironment-Related Genes.
Pan T; He Y; Chen H; Pei J; Li Y; Zeng R; Xia J; Zuo Y; Qin L; Chen S; Xiao L; Zhou H
Front Oncol; 2021; 11():614211. PubMed ID: 33692952
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma.
Liu C; Liu L
Front Genet; 2022; 13():1037716. PubMed ID: 36313435
[No Abstract] [Full Text] [Related]
11. Comprehensive analysis of the prognostic implication and immune infiltration of CISD2 in diffuse large B-cell lymphoma.
Zhang C; Lin Q; Li C; Qiu Y; Chen J; Zhu X
Front Immunol; 2023; 14():1277695. PubMed ID: 38155967
[TBL] [Abstract][Full Text] [Related]
12. Development and validation of a cuproptosis-associated prognostic model for diffuse large B-cell lymphoma.
Zhang B; Zhang T; Zheng Z; Lin Z; Wang Q; Zheng D; Chen Z; Ma Y
Front Oncol; 2022; 12():1020566. PubMed ID: 36713586
[TBL] [Abstract][Full Text] [Related]
13. Identification of microtubule-associated biomarkers in diffuse large B-cell lymphoma and prognosis prediction.
Wu W; Liu S; Tian L; Li C; Jiang Y; Wang J; Lv Y; Guo J; Xing D; Zhai Y; Sun H; Li Y; Zhang L; He X; Luo K; Zhan H; Zhao Z
Front Genet; 2022; 13():1092678. PubMed ID: 36761693
[No Abstract] [Full Text] [Related]
14. A Novel and Validated Inflammation-Based Prognosis Score (IBPS) Predicts Outcomes in Patients with Diffuse Large B-Cell Lymphoma.
Liu Y; Sheng L; Hua H; Zhou J; Zhao Y; Wang B
Cancer Manag Res; 2023; 15():651-666. PubMed ID: 37465083
[TBL] [Abstract][Full Text] [Related]
15. An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy.
Hu J; Xu J; Yu M; Gao Y; Liu R; Zhou H; Zhang W
J Transl Med; 2020 Mar; 18(1):144. PubMed ID: 32228625
[TBL] [Abstract][Full Text] [Related]
16. An Autophagy-Related Gene Signature can Better Predict Prognosis and Resistance in Diffuse Large B-Cell Lymphoma.
Zhou X; He YZ; Liu D; Lin CR; Liang D; Huang R; Wang L
Front Genet; 2022; 13():862179. PubMed ID: 35846146
[No Abstract] [Full Text] [Related]
17. Prediction significance of autophagy-related genes in survival probability and drug resistance in diffuse large B-cell lymphoma.
Xiong D; Wei X; Huang W; Zheng J; Feng R
Aging (Albany NY); 2024 Jan; 16(2):1049-1076. PubMed ID: 38240686
[TBL] [Abstract][Full Text] [Related]
18. Identification and Validation of a DNA Damage Repair-Related Signature for Diffuse Large B-Cell Lymphoma.
Li Y; Liu X; Chang Y; Fan B; Shangguan C; Chen H; Zhang L
Biomed Res Int; 2022; 2022():2645090. PubMed ID: 36281462
[TBL] [Abstract][Full Text] [Related]
19. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
20. Construction of a novel mRNA-signature prediction model for prognosis of bladder cancer based on a statistical analysis.
Li J; Cao J; Li P; Yao Z; Deng R; Ying L; Tian J
BMC Cancer; 2021 Jul; 21(1):858. PubMed ID: 34315402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
